Glenmark Pharmaceuticals Ltd
Company Profile
Business description
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
Contact
B. D. Sawant Marg
Glenmark House
Chakala, Off Western Express Highway
Andheri (East)
MumbaiMH400099
INDT: +91 2240189999
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
16,623
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,069.00 | 14.40 | -0.16% |
| CAC 40 | 8,103.58 | 0.27 | -0.00% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,731.16 | 288.75 | 0.60% |
| FTSE 100 | 9,870.68 | 18.54 | -0.19% |
| HKSE | 25,818.93 | 44.79 | 0.17% |
| NASDAQ | 23,613.31 | 51.46 | 0.22% |
| Nikkei 225 | 50,344.10 | 68.77 | -0.14% |
| NZX 50 Index | 13,529.06 | 11.33 | 0.08% |
| S&P 500 | 6,932.05 | 22.26 | 0.32% |
| S&P/ASX 200 | 8,762.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,940.95 | 20.97 | 0.53% |